Posted On: 09/18/2014 5:18:47 PM
Post# of 30066
Quote:
Based on the recent discussions by management in the business update call, as well as the discussions related to the possibility of entering into a big pharma bidding war over LymPro, I believe there may be a strategy to sell LymPro or even the entire diagnostics division to a BP after the division is spun out to a separate entity and after revenue is ramping up and there are more options using multiple biomarkers in the analysis. The sale of the diagnostics division would certainly be more complicated if a partnership with a big pharma already existed (especially one that wasn't the high bidder for the buyout). Perhaps the company inked the ICON master service agreement to enable them to bring LymPro to market and keep the legal requirements much simpler for the future bidding war/buyout of the diagnostics division.
That is a very real possibility. Like you have said there is no way possible to know what is going on behind the scenes. Exciting times ahead. No matter how long it takes, we are headed in the right direction. And I'm sleeping like a baby.
(0)
(0)
